Xagrid is a medicine used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets in the blood). ‘Essential’ means that the disease has no obvious cause. Xagrid is used when patients do not respond to or do not tolerate their current treatment, and when they are ‘at risk’ because of their age (over 60 years), very high platelet counts or previous clotting problems. Xagrid contains the active substance anagrelide.
Therapeutic Indication
### Therapeutic indication Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. **An at-risk patient** An at-risk ET is defined by one or more of the following features: - >60 years of age or; - a platelet count >1000 x 109/l or; - a history of thrombohaemorrhagic events.
Therapeutic Area (MeSH)
N/AATC Code
L01XX35
ATC Item
anagrelide
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| anagrelide | N/A | 阿那格雷 |
EMA Name
Xagrid
Medicine Name
Xagrid
Aliases
N/ANo risk management plan link.
